SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
Level 5, 126 Philip Street Sydney NSW 2000 GPO Box 5193 Sydney NSW 2001
Tel : 1300 288 664 or +61 2 9698 5414The suspension of trading in the securities of Invex Therapeutics Ltd will be lifted immediately following the release by IXC of an announcement regarding a material acquisition and the Company responding to a price query from ASX. | 30/09/2025 |
The company releases a response to an ASX price and volume query. | 30/09/2025 |
The company has discontinued exclusive negotiations with a therapeutic development company focused on a rare neurological disease due to instability from a requisition notice to remove 2 out of 3 Directors. The Board aims to continue its strategy of diversifying its portfolio by seeking complementary neurological treatment assets despite challenges in the current volatile environment. Following the completion of the Phase 3 IIH EVOLVE clinical trial, the Board has been reviewing various opportunities, but many were deemed unsuitable. In June 2025, a promising investment opportunity was identified in a complementary neurological treatment asset. | 30/09/2025 |
The company will hold its Annual General Meeting on 25 November 2025, with the closing date for director nominations being 7 October 2025. Shareholders will be informed in October 2025. | 29/09/2025 |
The company requests an extension to its voluntary suspension of securities trading, pending an announcement and response to ASX price query. The suspension remains in place until 30 September 2025. | 29/09/2025 |
The securities of Invex Therapeutics Limited will be suspended from quoting under Listing Rule 17.2 at IXC's request, pending an announcement. The suspension will continue until either the end of the requested voluntary suspension period or the announcement's release to the market. IXC's request is attached for market information. | 25/09/2025 |
listed entity carried for record purposes only | 05/07/2019 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 24/08/2023 | Thomas Duthy | 178,738 | $0.180 | $32,173.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Narelle Warren | CFO, Company Secretary | 05/07/2019 |
| David Wheeler | Non Exec Director | 08/11/2023 |
| Thomas Duthy | Executive Director | 01/10/2020 |
| David McAuliffe | Interim Chairman | 05/07/2019 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
